Arvato Moves EU Drug Verification System to Sovereign Cloud

Arvato Systems has moved its National Medicines Verification System to Oracle EU Sovereign Cloud, marking a significant shift in how prescription drugs are checked across Europe. The company now operates this critical infrastructure entirely within the European Union, specifically leveraging data centers in Madrid and Frankfurt. According to reporting by WebWire, this migration allows Arvato to process hundreds of millions of verification requests annually while strictly adhering to regional data residency laws.

The decision to leave on-premises servers was driven by the need for better scalability and easier management. Previously, maintaining separate physical environments for each of the 15 countries Arvato serves created operational bottlenecks. By centralizing these services in a cloud environment that remains legally and physically within the EU, the company aims to improve performance and availability for the over 100,000 healthcare providers who rely on the system daily to prevent counterfeit medicines from entering the supply chain.

Balancing Cloud Efficiency With Data Sovereignty

The core benefit of this setup is the ability to access modern cloud tools without sacrificing data control. Oracle EU Sovereign Cloud provides the same suite of over 200 AI and cloud services found in public cloud regions, but with a crucial distinction: the data centers are operated by EU legal entities and personnel. This structure helps Arvato meet stringent regulations like GDPR and C5, which are essential for handling sensitive healthcare data. The trade-off is that this specialized sovereign offering may carry higher operational costs or stricter governance requirements compared to standard public cloud providers, but it eliminates the risk of data leaving the jurisdiction.

For the end user, the change is largely invisible but impactful. The system now uses Oracle Exadata Database Service to dynamically scale resources as demand fluctuates. This means that during peak periods, the infrastructure can expand automatically to handle the load, reducing the risk of downtime. The implementation spans multiple availability domains in Madrid and Frankfurt, which strengthens disaster recovery capabilities and ensures that the service remains available even if one location experiences issues.

Streamlining Operations Across Fifteen Countries

One of the main operational advantages is the simplification of software updates and development. Instead of managing fifteen distinct on-premises environments, Arvato can now centralize testing and deployment. This reduces the complexity of keeping the system secure and up-to-date with the latest security patches and regulatory changes. The company stated that this centralization improves IT efficiency and allows for faster delivery of new features to the national verification organizations that rely on the platform.

However, this consolidation requires careful coordination to ensure that local regulatory nuances are still respected. The system must remain compliant with the specific requirements of each of the 15 countries it serves. By using a sovereign cloud framework aligned with EU and regional standards, Arvato positions itself to handle these complexities more effectively than with fragmented on-premises hardware. The move reflects a broader trend in European technology where organizations are seeking cloud capabilities without compromising on national sovereignty.

Enhancing Resilience For Critical Healthcare Services

The migration also strengthens the operational resilience of the drug verification process. By running critical databases on Oracle Exadata within the sovereign cloud, Arvato gains the ability to respond more quickly to changing market demands. This dynamic scaling is crucial for a service that handles a high volume of transactions, ensuring that pharmacies and hospitals can verify the authenticity of medicines without delays. The dual-location setup in Spain and Germany provides a robust disaster recovery strategy, minimizing the risk of service interruption.

Ultimately, the shift to Oracle EU Sovereign Cloud allows Arvato to modernize its infrastructure while maintaining the high level of security required for healthcare data. The company emphasizes that this approach gives them greater control over critical data assets, which is a key requirement for operating within the EU's regulatory landscape. As demand for digital health solutions grows, this model of sovereign cloud computing offers a viable path for other organizations seeking to balance technological advancement with strict data protection mandates.

Scaling verification while maintaining data residency

The migration addresses the operational strain of managing separate on-premises environments across 15 countries. By consolidating these services, Arvato Systems can now efficiently handle the millions of verification requests required to keep counterfeit medicines out of the supply chain.

Simultaneously, the move ensures that critical healthcare data stays local. Keeping the infrastructure within the EU allows the company to meet strict regional privacy and sovereignty regulations without sacrificing the scalability needed for such a high-volume service.